LMRILumexa Imaging Holdings Inc. Common Stock

Advanced imaging volumes surge as free cash flow hits record $23.1 million.

Lumexa Imaging Holdings Inc (LMRI) posts strong Q2 with record free cash flow, 23.2% PET volume growth, and a strategic New York JV, despite margin pressure from public company costs.

Lumexa Imaging (NASDAQ:LMRI) reported second-quarter revenue growth, higher advanced-imaging volumes and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reiterating revenue and adjusted earnings-per-share guidance. Chief Executive Officer Caitlin Zulla said the

Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.

The mean of analysts' price targets for Lumexa (LMRI) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

In Q1, we delivered several meaningful achievements to kick off a year at executing on our strategic priorities, which include driving strong same centric growth, an expanding mix of advanced modalities, targeting a record number of de novo openings, ensuring the successful ramp of newly opened centers, accelerating high impact strategic service lines, and expanding our geographic footprint. Specifically, we drove strong same center growth and strategic service lines are expanding among a healthy mix of advanced modalities. In Q1, advanced modalities grew 7% year over year with pet growing at 23.1% year over year and MRI growing at 8.2% year over year.